In the landscape of clinical trials, Pharma and Biotech companies consistently grapple with the critical challenge of efficiently accessing sufficient patient populations while ensuring the highest standards of study quality. Across the industry, sponsors face common obstacles: a shortage of high-performing sites with eligible patients, leading to study delays and unforeseen additional costs.

To address these pressing industry needs, CRU expanded its national site network into a Global Site Network in 2017. This strategic move was driven by a clear corporate objective: to provide our sponsors with precisely what they require—rapid access to large patient cohorts and the assurance of exceptional study quality, delivered in a timely manner.

Clinical site and CRO services in Europe, US and Asia